The International Council for Harmonisation has finalized three key guidelines at its latest meeting in Singapore, including the highly-debated quality guideline (ICH Q12) on lifecycle management of post approval changes.
The other two guidelines that have been finalized are the ICH E9(R1) addendum to defining the appropriate estimand for a clinical trial/sensitivity analyses, and the ICH M9 guideline
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?